Parkinson's Disease - Patient Pool Analysis & Market Outlook

What is Parkinson's disease?
Parkinson's disease (PD) is a chronic, progressive neurodegenerative disorder caused by loss of dopaminergic neurons in the substantia nigra. Core clinical features include:
• Resting tremor, rigidity, bradykinesia and postural instability
• Non-motor symptoms (sleep disorders, depression, cognitive decline, constipation, autonomic dysfunction)
• Strong age association - predominantly affects people over 60, but young-onset cases are increasingly recognised
There is no cure; current therapies are mainly symptomatic (levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, device-aided therapies like deep brain stimulation).

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72102

Global patient pool - high-level view
Global burden
• WHO estimated >8.5 million people living with Parkinson's disease in 2019, and noted that prevalence has doubled over the last 25 years.
• A major global analysis reported an all-age prevalence of ~1.51 cases per 1,000 population worldwide, with age-standardized prevalence rising steadily over the last three decades.
• New BMJ modelling projects that global PD cases will reach ~25.2 million by 2050, a 112% increase vs 2021, driven largely by population aging in East and South Asia.
Incidence highlights
• In North America, a large 2022 study found that PD incidence in people ≥65 years ranged roughly 108-212 per 100,000 person-years, confirming PD as one of the most common neurodegenerative disorders in older adults.
• The Parkinson's Foundation now cites ~90,000 new PD diagnoses per year in the US alone, about 50% higher than older estimates of 60,000/year.
In practical terms: PD is already a high-prevalence neurodegenerative disease (millions of patients) and is on track to become one of the fastest-growing neurological disorders worldwide.

7MM diagnosed patient pool
The 7MM (US, EU5, UK, Japan) is well-characterized epidemiologically and forms the core pharma market.
• DelveInsight and GlobalData estimate ~2.6-2.7 million diagnosed prevalent PD cases in the 7MM in 2023.
• DelveInsight reports that diagnosed prevalent cases reached ~3 million in 2024, with numbers projected to rise steadily through 2034.
• A GlobalData epidemiology update projects diagnosed prevalent cases in the 7MM rising from 2.64 million (2023) to 3.15 million by 2033, implying an average annual growth rate of ~1.9% over that period.

Rough distribution within 7MM (DelveInsight):
• United States - about 45% of diagnosed prevalent cases
• EU4 + UK - around 46-50% combined, with Germany the largest European contributor
• Japan - roughly 9% of the 7MM pool

Age and stage
• 90% of diagnosed patients in the 7MM are ≥60 years old, with prevalence peaking in the 75-85 age band.
• Stage-specific analyses (e.g., DelveInsight) show the bulk of patients in Hoehn & Yahr stages II-III, with smaller but important segments in early (I) and advanced (IV-V) disease that drive device-aided therapy and caregiver-intensive care.

Global market size and growth outlook
Because different firms define the scope slightly differently (drugs only vs total therapeutics), estimates vary, but they converge on strong mid-single to high-single-digit growth.
Recent global estimates
• Fortune Business Insights (PD drugs only):
o USD 7.17 billion in 2024 → USD 13.46 billion by 2032, CAGR ~8.2%.
• Global Market Insights (therapeutics):
o USD 6.2 billion in 2024 → USD 13.3 billion by 2034, CAGR 8.1% (2025-2034).
• Grand View Research (treatments):
o USD 5.65 billion in 2024 → USD 7.58 billion by 2030, CAGR ~5.0% (2025-2030).
• Precedence Research / GlobeNewswire (therapeutics):
o USD 6.59 billion in 2024 → USD 13.34 billion by 2034, CAGR ~7.4% (2025-2034).
For your client-facing positioning, a robust consensus statement is:
• 2024-2025 global Parkinson's disease treatment/therapeutics market:
roughly USD 5-7 billion
• 2032-2034 outlook:
approximately USD 9-13+ billion
• Implied CAGR:
~6-8% over the forecast period
7MM market
• One 7MM-focused analysis estimated PD drug sales at about USD 3.4 billion across the 7MM in 2023, with forecasts approaching USD ~7.9-8.0 billion by 2033, driven by both volume and mix-shift to newer agents and device-aided therapies.

High-level market segmentation
By therapy class
• Dopaminergic replacement:
o Levodopa and combinations, dopamine agonists (pramipexole, ropinirole, rotigotine), MAO-B inhibitors (rasagiline, selegiline, safinamide), COMT inhibitors - backbone of standard care and majority of prescription volume.
• Advanced and device-aided therapies:
o Deep brain stimulation (DBS), continuous subcutaneous levodopa/carbidopa or apomorphine infusions, intestinal gel formulations - smaller patient numbers but high per-patient spend.
• Symptom-specific and adjunctive agents:
o Treatments for PD psychosis, motor fluctuations, OFF time, and non-motor symptoms (e.g., pimavanserin, opicapone, istradefylline), plus pipeline gene and cell therapies.

By disease stage
• Early-stage PD: high patient volume, dominated by oral dopaminergic drugs.
• Mid-stage PD with motor complications: increasing reliance on add-ons, device-aided options, and more complex regimens.
• Advanced PD: smaller pool but very high resource utilization (DBS, infusions, frequent hospitalizations, caregiver and institutional care).

By region
• North America - largest revenue share; highest uptake of newer agents and DBS.
• Europe - large, aging population with good access; growth shaped by HTA and pricing pressure but strong baseline prevalence.
• Asia-Pacific - fastest growth, especially China, India, Japan and South Korea, reflecting demographic aging and increasing neurologist density.

Explore Full Report here: https://exactitudeconsultancy.com/reports/72102/parkinson-s-disease-patient-pool-analysis-market

Key drivers and strategic takeaways
• Rapidly aging populations in East/South Asia and high-income regions will keep patient numbers and treatment demand rising.
• Diagnosis and awareness are improving, especially for early and young-onset PD, expanding the addressable treated pool.
• Therapeutic innovation (extended-release levodopa, new add-on drugs, non-oral routes, cell and gene-therapy pipelines) is expected to lift average revenue per patient even in mature markets.
• Health-system burden (long-term disability, caregiver strain, institutional care) supports payer willingness to reimburse interventions that delay progression or reduce complications.

How you can reuse this
You can summarise Parkinson's disease in your reports as:
• Patient pool:
o Global: >8.5 million patients in 2019, projected ~25 million by 2050.
o 7MM: ~2.6-2.7 million diagnosed prevalent cases in 2023, ~3 million in 2024, growing to ~3.1-3.2 million by 2033.
• Market:
o Global PD treatment/therapeutics market: USD 5-7 billion (2024) → ~USD 9-13+ billion (early/mid-2030s), CAGR ~6-8%.
o 7MM drug market: roughly USD ~3.4 billion (2023) → ~USD 7.9-8 billion (2033).

This report is also available in the following languages : Japanese (パーキンソン病患者プール分析、市場), Korean (파킨슨병 환자 풀 분석, 시장), Chinese (帕金森病患者群体分析,市场), French (Analyse du marché des patients atteints de la maladie de Parkinson), German (Analyse des Patientenpools für Parkinson-Patienten, Markt), and Italian (Analisi del bacino di pazienti affetti dalla malattia di Parkinson, mercato), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/72102

Our More Reports:

Cell and Gene Therapy Supply Chain Software Market
https://exactitudeconsultancy.com/reports/44540/cell-and-gene-therapy-supply-chain-software-market

Medical Cryogenic Storage Equipment Market
https://exactitudeconsultancy.com/reports/48386/medical-cryogenic-storage-equipment-market

Biologics Market
https://exactitudeconsultancy.com/reports/49003/biologics-market

Global Cell and Gene Therapy Solutions Market
https://exactitudeconsultancy.com/reports/59710/global-cell-and-gene-therapy-solutions-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.